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SHORT COMMUNICATION
p53 mutation is associated with high S-phase fraction in primary fallopian
tube adenocarcinoma
IB Runnebaum, T Kohler, E Stickeler, HE Rosenthal DG Kieback and R Kreienberg
Department ofObstetrics and Gynaecology, Molecular Biology Laboratory, University of Ulm, 89075 Ulm, Germany.
Summary Fallopian tube carcinoma (FTC) is a rare but lethal gynaecological malignancy. Four out of seven
FTCs were identified with three point missense mutations, one single base deletion and one silent point
mutation in the p53 gene. Genital-type HPV sequences were not detected. The S-phase fraction of tumours with
mutant and wild-type p53 was 25.74% (median) and 12.55% (median) respectively.
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Primary fallopian tube carcinoma (FTC) is an aggressive,
malignant tumour of the female genital tract with an
unfavourable prognosis and an approximately 10% 5 year
survival in the later stages (Eddy et al., 1984; Rose et al.,
1990; Rosen et al., 1993). FTCs are rare, constituting about
1% of all female genital tract cancers. The vast majority
represent adenocarcinomas and show histopathological
similarities to epithelial ovarian cancer. In non-familial
ovarian cancer, alteration of the p53 tumour-suppressor
gene by somatic mutation is the most common single-gene
alteration identified so far (Marks et al., 1991; Okamoto et
al., 1991; Tsao et al., 1991; Kupryjanczyk et al., 1993; Milner
et al., 1993; Runnebaum et al., 1994a; Runnebaum et al.,
1995a). Wild-type p53 is a potent suppressor of tumorigenesis
in different tumour types (Eliyahu et al., 1989; Baker et al.,
1990; Cheng et al., 1992; Runnebaum et al., 1994c;
Runnebaum and Kreienberg 1995). p53 acts as a transcrip-
tion factor (Kern et al., 1991; Unger et al., 1992) regulating
cellular functions such as DNA damage response (Kastan et
al., 1991, 1992), induction of apoptosis by transactivating
Bax and transrepressing Bcl-2 (Miyashita et al., 1994;
Miyashita and Reed, 1995) or inducing G1 cell cycle arrest
by transactivating p2iWAFI/CIPI (Lowe and Ruley 1993;
Yonish-Rouach et al., 1993; Runnebaum et al., 1995b). A
p53 mutation in FTC has first been identified in the cell line
FT-MZ-1 established in our laboratory (Runnebaum et al.,
1994b). We tested primary FTCs for p53 gene mutation and
aberrant protein accumulation, integration of human
papillomavirus (HPV) sequences and the association of cell
cycle parameters with p53 alterations.
Material and methods
Pretreatment tumour samples from seven German Caucasian
patients diagnosed with primary fallopian tube adenocarci-
noma between 1986 and 1993 were analysed. Abdominal
hysterectomy with bilateral salpingo-oophorectomy, resection
of the omentum and retroperitoneal lymphadenectomy were
performed. The tumour specimens contained more than 90%
tumour cells as examined on haematoxylin and eosin stained
sections taken from the same tumour block preceding and
subsequent to the segment analysed. Tissue sections were
analysed by two pathologists.
Mutation screening of the entire coding region comprising
exon 2 to 11 was carried out using genomic tumour DNA
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extracted from the paraffin-embedded formalin-fixed sections
as described previously (Runnebaum et al., 1991, 1994b).
Polymerase chain reaction (PCR) fragments were sequenced
on an automated sequencer (ALF express, Pharmacia
Biotech, Uppsala, Sweden). Sense and antisense strands
were analysed three times each. Ovarian cancer cell lines
with characterised p53 mutations served as positive controls.
The p53 protein was detected by immunohistochemistry with
the anti-(human)p53 mouse monoclonal antibody DO-1
(Dianova, Hamburg, Germany). Cell line FT-MZ-1, with a
point missense mutation in codon 175 of the p53 gene, served
as a control for positive staining (Runnebaum et al., 1994b).
The evaluation was performed by two investigators unaware
of the results of the molecular analysis. An immunoreactive
score (IRS, see Table II) was assessed for recording staining
intensity and proportion of stained cells (Remmele and
Stegner 1987; Runnebaum et al., 1996).
Genital-type HPV sequences were screened for using an
LI gene consensus primer PCR and dot blot analysis as well
as an E6 gene multiplex PCR (Runnebaum et al., 1995c).
Genomic DNA from the cervical cancer cell lines HeLa (10
to 50 integrated copies of HPV 18 per genome), SiHa (one
to two integrated copies of HPV 16) and CaSki (500 to 600
integrated copies of HPV 16) cells served as positive
controls.
Flow cytometric analysis (Becton-Dickinson) was carried
out using sections of 30 ,Im. The samples were coded and the
experiments were carried out in a blinded fashion to eliminate
observer bias.
Results
Seven patients with fallopian tube adenocarcinoma were
included in the study. Four patients had stage IIA disease
(Table I), according to the staging classification of the
International Federation of Gynaecologists and Obstetricians
(FIGO) with extension to the uterus or the ovaries (Nordin,
1994). Three other patients had a FIGO stage IIIC (Table I)
Table I Patient and tumour characteristics
Tumour Patient's age FIGO
DNA no. (years) stage Grade Histology
339 52 IIA 3 Papillary
459 57 IIIC 3 Papillary
777 65 IIIC 3 Papillary
906 67 IIA 2 Papillary
1417 56 IIA 2 Papillary
1773 69 IIA 3 Papillary
6097 52 IIIC 3 Papillaryp53 and S-phase in fallopian tube carcinoma
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Table II p53 alterations
Tumour DNA Mutation in Mutation Immunoreactive
no. codon Nucleotide sequence type Heterozygosity Amino acid substitution scorea
339 277 TGT to TAT TIb Yes Cys to Tyr 2
459 Wild-type 0
777 194 CTT to CT DELC Yes Frame shift 8
777 267 CGG to CGA TI Yes Silent
906 285 GAG to AAG TI No Glu to Lys 12
1417 Wild-type 2
1773 Wild-type 0
6097 175 CGC to CAC TI No Arg to His 12
aThe immunoreactive score (IRS) records intensity and proportion ofstained cells by multiplication ofthe proportion score PP (PP=0, no
staining; PP= 1, staining in < 10% ofcells; PP =2, staining in 10-50% ofcells; PP =3, staining in 51-80% ofcells; PP =4, staining in > 80%
ofcells) and the staining intensity score SI (SI =0, no staining; SI = 1, weak staining; SI =2, marked staining; SI =3, strong staining). bTI,
transition mutation. CDEL, deletion mutation.
of the disease with intraabdominal spread. Tumour no. 777
had metastasised to paraaortic lymph nodes.
Five mutations were identified by nucleotide sequencing
(Table II). Two mutations were identified in tumour no. 777,
one silent point mutation in exon 8 not leading to an amino
acid change and one single base deletion in exon 6 shifting
the reading frame (Figure 1). The presence of mutant (mt)
and wild-type (wt) sequence in nos. 339 and 777 indicated
heterozygosity at the p53 locus.
Immunohistochemistry showed accumulation of p53
protein with a marked stain in three tumours. In tumours
906, with a homozygous point missense mutation in codon
285, and 6097, with the Hisl75 mutant, the strong stain of
more than 80% of the tumour cells resulted in an IRS of 12
(Figure 2). Tumour no. 777 showed an intermediate staining
intensity in more than 80% of the cells with an IRS of 8
(Figure 2). Two tumours stained weakly with few cells (IRS
2), i.e. tumour no. 339 with an identified p53 point missense
mutation and tumour no. 1417 with wild-type p53. Two
tumours showed no detectable p53 expression (data not
shown).
Integrated HPV sequences were found in none of the
FTCs as tested by LI consensus primer PCR and dot blot.
No HPV16-E6 or HPV18-E6 oncogene was detectable by
multiplex PCR (data not shown).
The results of the FACScan analysis of the cell cycle
distribution are summarised in Table III. The percentage of
cells in S-phase varied between 7.06% and 33.90% in the
different tumour samples. The S-phase fraction of tumours
with mutant p53 was 25.74% (median) and of tumours with
wild-type pS3, 12.55% (median). The GI/Go fractions varied
between 58.84% and 82.60%. The median GI/Go fraction of
mutant p53 samples was 62.82% (median) and of wild-type
p53 samples, 82.48% (median). All FTC samples were
diploid.
No. 339
Codon 277
TGT-*TAT
No. 777
Codon194
CTT->CT
No. 777
Codon 267
CGG--CGA
No. 906
Codon 285
GAG- AAG
CC GG CGCAC AAA G GAAG AGA
Discussion
The majority of FTCs are adenocarcinomas, stages II or III
(Eddy et al., 1984; Rosen et al., 1993; Lacy et al., 1995). The
tumours in this study were papillary adenocarcinomas
representative for FTC. The tumours were metastatic at the
time of diagnosis with FIGO stages IIA and IIIC (Nordin,
1994). In four out of seven FTCs, mutations in the p53
tumour-suppressor gene were identified. The four point
mutations were transition mutations, three of which changed
the primary amino acid sequence. p53 transition mutations
have frequently been found in other carcinoma types such as
ovarian cancer, breast cancer and colon cancer and are
considered to occur spontaneously. The point mutation in
tumour no. 777 occurred at the third base position of codon
267 as a silent mutation. In the same tumour, an additional
p53 mutation was found. The single base deletion in codon
194 leads to a frame shift. Small deletions could be caused by
DNA replication errors and appear to occur relatively
Figure 1 Representative nucleotide sequence readings in sense
direction of the p53 gene of three fallopian tube carcinomas. The
arrowheads indicate the position of the missense of frameshift
mutation.
frequently in ovarian cancer (Okamoto et al., 1991; Milner
et al., 1993; Runnebaum et al., 1994a). The loss of
heterozygosity (LOH) rate at the p53 gene locus on
chromosome arm 17p is not known for FTC. In various
tumours the rate of LOH at this locus exceeds the rate ofp53
mutations. Two out of four FTCs with mutant p53, however,
remained heterozygous at the p53 locus.
The identified mutations were located in the 'core region',
which comprises codons 102 to 292 of the p53 gene (Cho et
al., 1994). The core region conveys the sequence-specific
DNA-binding activity, a key function for the biological effect
of p53. Missense mutations in this region are commonlyp53 and S-phaein fopian t ar
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Figur 2 Immunohistochemical analvsis of p513 expression in
fallopian tube carcinomias. (a) No. 6097. DO-i. (b) No. 6097.
negative control. (c) No. 777. DO-i. (d) No. 777. negative control.
Size bar=20m
reflected bv a nuclear accumulation of p53 protein stabilised
in a denatured state (Cho et al. 1994) Studies have been
conducted based on immunohistochemincal screening to
establish accumulation of p53 protein as a marker of
prognostic significance in diverse tumour types. Accumula-
tion of p53 as studied in 43 FTC cases has not been found to
Table III p53 status and cell cycle parameters
Tumour no. p53 status Go GI 1 % v S (%, G, tf l (,
339 Mutant 71.33 24.44 4.23
777 Mutant 64.48 23.12 12.40
906 Mutant 61.16 33.90 4.94
6097 Mutant 58.84 27.03 14.13
459 Wild-type 82.60 12.55 4.85
1417 Wild-type 65.49 16.37 18.14
1773 Wild-type 82.48 7.06 10.46
predict clinical outcome (Lacy et al.. 1995): the staining
intensity but not the fraction of stained cells was recorded.
Superior to the assessment of staining intensity or percentage
of stained cells alone could be the IRS as demonstrated in a
study on the prognostic value of steroid receptor expression
in ovarian cancer (Kieback et al.. 1993). Not all point
missense mutations lead to accumulation of denatured p53
protein which was observed in one out of four tumours with
p53 missense mutations in our study. An immunohistochem-
ical study without molecular analysis may therefore
mistakenly rate a significant number of tumours as contain-
ing wild-type p53. It appears difficult to value p53
immunohistochemical data with regard to clinical outcome.
Binding ofp53 to the HPV E6 oncogene product mediated
by the E6-associated protein has been shown to be a
mechanism of p53 inactivation in squamous cell carcinoma
of the cervix. Genital-type HPV sequences were not detected
in the seven FTC samples analysed. HPV-related p53
inactivation (Scheffner et al.. 1990) may not play a role in
the development of FTC.
FTCs with mutant p53 presented with a higher S-phase.
even in the p53 heterozygous tumours. Wild-type p53 protein.
increased by DNA damage. transcriptionally induces
p21%AF' clPl (El-Deiry et al., 1993; Harper et al.. 1993).
p2lWAFI CIPI complexes with and inhibits factors essential for
cell cycle progression at the G, checkpoint and DNA
replication, cyclin-dependent kinases and the proliferating
cell nuclear antigen (PCNA) (Chen et al.. 1995: Luo et al..
1995). In the p53 heterozygous tumour no. 339. wild-type p53
may be inactivated in the presence of a dominant negative
mutant protein possibly sequestering the wild-type protein by
oligomerisation (Clore et al.. 1994).
In a small number of fallopian tube cancers. we have
demonstrated that the p53 tumour-suppressor gene can be
mutated with accumulation of aberrant p53 protein. FTCs
with a p53 mutation may present with a higher S and a lower
G, Go fraction. Larger studies will define the role of p53
mutation and cell cycle parameters as indicators of clinical
outcome. Because of the rarity of FTC. such studies could
best be performed in multicentre cooperative study groups.
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